After Immunomedics announced a partnership with Everest Medicines to commercialize sacituzumab for all cancer indications in Asian countries including China and South Korea, Piper Jaffray analyst Joseph Catanzaro called the terms of the deal "very favorable," adding that he believes they "set a new benchmark for greater China licensing deals." Catanzaro also addressed the news that Chief Medical Officer Rob Iannone has decided to leave the company for personal reasons, telling investors that he does not believe the change will affect the company's resubmission process for sacituzumab's BLA. The analyst keeps an Overweight rating and $20 price target on Immunomedics shares.